France Meningococcal Vaccines Market Size & Outlook
France meningococcal vaccines market, 2018-2030 (US$M)
Related Markets
France meningococcal vaccines market highlights
- The France meningococcal vaccines market generated a revenue of USD 116.0 million in 2021 and is expected to reach USD 212.6 million by 2030.
- The France market is expected to grow at a CAGR of 7% from 2022 to 2030.
- In terms of segment, bivalent was the largest revenue generating type in 2021.
- Quadrivalent is the most lucrative type segment registering the fastest growth during the forecast period.
Meningococcal vaccines market data book summary
| Market revenue in 2021 | USD 116.0 million |
| Market revenue in 2030 | USD 212.6 million |
| Growth rate | 7% (CAGR from 2021 to 2030) |
| Largest segment | Bivalent |
| Fastest growing segment | Quadrivalent |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bivalent, Quadrivalent |
| Key market players worldwide | Pfizer Inc, Sanofi SA, GSK PLC, Merck & Co Inc, Serum Institute of India Pvt. Ltd., Walvax Biotechnology |
Other key industry trends
- In terms of revenue, France accounted for 4.0% of the global meningococcal vaccines market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK meningococcal vaccines market is projected to lead the regional market in terms of revenue in 2030.
- Russia is the fastest growing regional market in Europe and is projected to reach USD 27.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Meningococcal Vaccines Market Scope
Meningococcal Vaccines Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
France meningococcal vaccines market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to meningococcal vaccines market will help companies and investors design strategic landscapes.
Bivalent was the largest segment with a revenue share of 62.16% in 2021. Horizon Databook has segmented the France meningococcal vaccines market based on bivalent, quadrivalent covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing approval and development of new vaccines by local key players is anticipated to drive market penetration in other countries, thereby boosting market growth. For instance, in November 2020, Sanofi, a French company, received the European Commission approval for Men Quadfi for immunization of children and adults.
Increasing campaigns by the government & organizations to defeat meningitis are expected to fuel market growth. For instance, in 2017, there were 74 cases of serogroup W. Moreover, from October 2018 to March 2019, a vaccination campaign was scheduled by Regional Agency for Health or ARS against serogroup W.
Despite the introduction of vaccination program for meningococcal C disease, France is the only European country in which the prevalence of disease is increasing. However, a significant decline has been observed in the prevalence of this disease in 2020 due to implementation of stringent COVID-19 control.
Reasons to subscribe to France meningococcal vaccines market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of France meningococcal vaccines market databook
-
Our clientele includes a mix of meningococcal vaccines market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the France meningococcal vaccines market , including forecasts for subscribers. This country databook contains high-level insights into France meningococcal vaccines market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
France meningococcal vaccines market size, by type, 2018-2030 (US$M)
France Meningococcal Vaccines Market Outlook Share, 2021 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
